Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Selenoproteins and oxidative stress-induced inflammatory tumorigenesis in the gut.

Barrett CW, Short SP, Williams CS.

Cell Mol Life Sci. 2017 Feb;74(4):607-616. doi: 10.1007/s00018-016-2339-2. Epub 2016 Aug 25. Review.

PMID:
27563706
2.

Prevention of colorectal cancer and dietary management.

Hou N, Huo D, Dignam JJ.

Chin Clin Oncol. 2013 Jun;2(2):13. doi: 10.3978/j.issn.2304-3865.2013.04.03.

3.

Macro- and micronutrients consumption and the risk for colorectal cancer among Jordanians.

Tayyem RF, Bawadi HA, Shehadah IN, Abu-Mweis SS, Agraib LM, Bani-Hani KE, Al-Jaberi T, Al-Nusairr M, Heath DD.

Nutrients. 2015 Mar 10;7(3):1769-86. doi: 10.3390/nu7031769.

4.

Diet and supplements and their impact on colorectal cancer.

Pericleous M, Mandair D, Caplin ME.

J Gastrointest Oncol. 2013 Dec;4(4):409-23. doi: 10.3978/j.issn.2078-6891.2013.003. Review.

5.

Toward understanding success and failures in the use of selenium for cancer prevention.

Steinbrenner H, Speckmann B, Sies H.

Antioxid Redox Signal. 2013 Jul 10;19(2):181-91. doi: 10.1089/ars.2013.5246. Epub 2013 Mar 21. Review.

6.

Design and baseline characteristics of participants in a phase III randomized trial of celecoxib and selenium for colorectal adenoma prevention.

Thompson P, Roe DJ, Fales L, Buckmeier J, Wang F, Hamilton SR, Bhattacharyya A, Green S, Hsu CH, Chow HH, Ahnen DJ, Boland CR, Heigh RI, Fay DE, Martinez ME, Jacobs E, Ashbeck EL, Alberts DS, Lance P.

Cancer Prev Res (Phila). 2012 Dec;5(12):1381-93. doi: 10.1158/1940-6207.CAPR-12-0204. Epub 2012 Oct 11.

7.

Selenoprotein P status correlates to cancer-specific mortality in renal cancer patients.

Meyer HA, Endermann T, Stephan C, Stoedter M, Behrends T, Wolff I, Jung K, Schomburg L.

PLoS One. 2012;7(10):e46644. doi: 10.1371/journal.pone.0046644. Epub 2012 Oct 9.

8.

Clinical end points for developing pharmaceuticals to manage patients with a sporadic or genetic risk of colorectal cancer.

Rial NS, Zell JA, Cohen AM, Gerner EW.

Expert Rev Gastroenterol Hepatol. 2012 Aug;6(4):507-17. doi: 10.1586/egh.12.23. Review.

9.

Deficiency in the 15 kDa selenoprotein inhibits human colon cancer cell growth.

Tsuji PA, Naranjo-Suarez S, Carlson BA, Tobe R, Yoo MH, Davis CD.

Nutrients. 2011 Sep;3(9):805-17. doi: 10.3390/nu3090805. Epub 2011 Sep 5.

10.

Differential effects of selenium and knock-down of glutathione peroxidases on TNFα and flagellin inflammatory responses in gut epithelial cells.

Gong G, Méplan C, Gautrey H, Hall J, Hesketh JE.

Genes Nutr. 2012 Apr;7(2):167-78. doi: 10.1007/s12263-011-0256-4. Epub 2011 Nov 9.

11.

Phenylbutyl isoselenocyanate modulates phase I and II enzymes and inhibits 4-(methylnitrosamino)-1-(3-pyridyl)- 1-butanone-induced DNA adducts in mice.

Crampsie MA, Jones N, Das A, Aliaga C, Desai D, Lazarus P, Amin S, Sharma AK.

Cancer Prev Res (Phila). 2011 Nov;4(11):1884-94. doi: 10.1158/1940-6207.CAPR-11-0221. Epub 2011 Jul 27.

12.

Serum selenium, genetic variation in selenoenzymes, and risk of colorectal cancer: primary analysis from the Women's Health Initiative Observational Study and meta-analysis.

Takata Y, Kristal AR, King IB, Song X, Diamond AM, Foster CB, Hutter CM, Hsu L, Duggan DJ, Langer RD, Petrovitch H, Shikany JM, Vaughan TL, Lampe JW, Prentice RL, Peters U.

Cancer Epidemiol Biomarkers Prev. 2011 Sep;20(9):1822-30. doi: 10.1158/1055-9965.EPI-11-0364. Epub 2011 Jul 15.

13.

The Akt inhibitor ISC-4 activates prostate apoptosis response protein-4 and reduces colon tumor growth in a nude mouse model.

Sharma AK, Kline CL, Berg A, Amin S, Irby RB.

Clin Cancer Res. 2011 Jul 1;17(13):4474-83. doi: 10.1158/1078-0432.CCR-10-2370. Epub 2011 May 9.

14.

Induction of glutathione peroxidase 4 expression during enterocytic cell differentiation.

Speckmann B, Bidmon HJ, Pinto A, Anlauf M, Sies H, Steinbrenner H.

J Biol Chem. 2011 Mar 25;286(12):10764-72. doi: 10.1074/jbc.M110.216028. Epub 2011 Jan 20.

15.

Glutathione peroxidase-1 in health and disease: from molecular mechanisms to therapeutic opportunities.

Lubos E, Loscalzo J, Handy DE.

Antioxid Redox Signal. 2011 Oct 1;15(7):1957-97. doi: 10.1089/ars.2010.3586. Epub 2011 Apr 10. Review.

16.

Polymorphisms in the selenoprotein S and 15-kDa selenoprotein genes are associated with altered susceptibility to colorectal cancer.

Sutherland A, Kim DH, Relton C, Ahn YO, Hesketh J.

Genes Nutr. 2010 Sep;5(3):215-23. doi: 10.1007/s12263-010-0176-8. Epub 2010 May 13.

17.

Trace elements and vitamin E status in Nigerian patients with prostate cancer.

Adaramoye OA, Akinloye O, Olatunji IK.

Afr Health Sci. 2010 Mar;10(1):2-8.

18.

Primary prevention of colorectal cancer.

Chan AT, Giovannucci EL.

Gastroenterology. 2010 Jun;138(6):2029-2043.e10. doi: 10.1053/j.gastro.2010.01.057. Review.

19.

Antioxidant and DNA methylation-related nutrients and risk of distal colorectal cancer.

Williams CD, Satia JA, Adair LS, Stevens J, Galanko J, Keku TO, Sandler RS.

Cancer Causes Control. 2010 Aug;21(8):1171-81. doi: 10.1007/s10552-010-9544-3. Epub 2010 Mar 30.

20.

Molecular mechanisms by which selenoproteins affect cancer risk and progression.

Zhuo P, Diamond AM.

Biochim Biophys Acta. 2009 Nov;1790(11):1546-54. doi: 10.1016/j.bbagen.2009.03.004. Epub 2009 Mar 13. Review.

Supplemental Content

Support Center